Ultane (sevoflurane)
November 20, 2003
Audience: Anesthesia healthcare professionals
Abbott Laboratories issued a "Dear Healthcare Professional" letter concerning reports of fire or extreme heat in the respiratory circuit of anesthesia machines when Ultane is used in conjunction with a desiccated CO2 absorbent, which can result in patient injury. Ultane is indicated for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery. The letter provided suggestions to reduce the risk of occurrence of these adverse events. Abbott, in collaboration with the FDA, is investigating the causative and preventive factors surrounding the issues of fire, extreme heat, and potential breakdown products associated with the use of Ultane and desiccated CO2 absorbents.[November 17, 2003 Letter - Abbott]
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.